The impact of an "evergreening" strategy nearing patent expiration on the uptake of biosimilars and public healthcare costs : a case study on the introduction of a second administration form of trastuzumab in The Netherlands
Ghyli Kirshner, Peter Makai, Chiara Brouns, Lonneke Timmers, Ron Kemp
| Year of publication: |
2024
|
|---|---|
| Authors: | Kirshner, Ghyli ; Makai, Peter ; Brouns, Chiara ; Timmers, Lonneke ; Kemp, Ron |
| Published in: |
The European journal of health economics. - Berlin : Springer, ISSN 1618-7601, ZDB-ID 2011428-X. - Vol. 25.2024, 7, p. 1147-1163
|
| Subject: | Biosimilar | Competition | Evergreening | Pricing | Niederlande | Netherlands | Gesundheitskosten | Health care costs | Arzneimittel | Pharmaceuticals | Patent | Gesundheitswesen | Health care system |
| Type of publication: | Article |
|---|---|
| Type of publication (narrower categories): | Aufsatz in Zeitschrift ; Article in journal |
| Language: | English |
| Other identifiers: | 10.1007/s10198-023-01648-w [DOI] |
| Source: | ECONIS - Online Catalogue of the ZBW |
Persistent link: https://www.econbiz.de/10015141769